Continuing the Success Story With TRK Inhibitors

David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.

EP. 1: Molecular Testing Strategies to Identify NTRK Gene Fusions

March 25th 2021

Current preferences for testing patients with advanced solid tumors for NTRK gene fusions to help guide therapy based on treatment advances for TRK fusion-positive solid tumors.

EP. 2: TRK Inhibitors for Advanced Solid Tumors

March 25th 2021

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses the availability of TRK inhibitors to treat advanced TRK fusion-positive solid tumors, highlighting their safety and efficacy.

EP. 3: Larotrectinib and CNS Metastasis in TRK Fusion-Positive Tumors

March 25th 2021

The significance of recent data exploring larotrectinib, a TRK inhibitor, in a subset of patients with TRK fusion–positive tumors with CNS (central nervous system) metastasis.

EP. 4: Treatment Considerations for TRK Fusion-Positive NSCLC

March 25th 2021

Dr David S. Hong reacts to updated survival data associated with the use of larotrectinib as treatment for TRK fusion–positive non–small cell lung cancer.

EP. 5: TRK Inhibitors for Advanced Thyroid Cancers

March 25th 2021

Important takeaways from recent safety and efficacy data presented on the use of larotrectinib as treatment for advanced differentiated and anaplastic thyroid cancers with NTRK gene fusions.

EP. 6: TRK Inhibitors for Advanced Solid Tumors: Next Steps in Research

March 25th 2021

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, shares his enthusiasm for ongoing research efforts to optimize treatment for patients with advanced solid tumors who harbor NTRK gene fusions.